BioInsights - Vol 6 Issue 1

CELL & GENE THERAPY INSIGHTS

February 2020 Issue

Vol 6 Issue 1

Download

Featuring

Issue Spotlight: Preclinical and translational R&D insights
Focus: Suspension Culture Methods
Other articles
Webinars

SPOTLIGHT

Preclinical and translational R&D insights
Karen Kozarsky
Guest Editor:
Karen Kozarsky, CSO at Swan Biotherapeutics

Editorial

From laboratory to patients: dissecting obstacles in cell & gene therapy development

From laboratory to patients: dissecting obstacles in cell & gene therapy development

D Silva, C Spano, M Varricchio et al.
28 February 2020
Read

Expert Insight

Manufacturing of human iPSC-derived cell therapies: road to the clinic

Manufacturing of human iPSC-derived cell therapies: road to the clinic

Raquel Martín-Ibáñez, Dhruv Sareen
27 February 2020
Read
The rise of human induced pluripotent stem cell technology in drug development

The rise of human induced pluripotent stem cell technology in drug development

Chun Liu, Joseph Wu
21 February 2020
Read
Vascular microphysiological systems to model diseases

Vascular microphysiological systems to model diseases

Q Zhang, X Zhang, G Truskey
14 February 2020
Read

Perspective

Complexity be damned: the need to better use biology to achieve more impactful cell therapies

Complexity be damned: the need to better use biology to achieve more impactful cell therapies

Nancy L Parenteau
3 February 2020
Read

Interview

Streamlining preclinical-clinical translation processes for an expanding CGT pipeline

Streamlining preclinical-clinical translation processes for an expanding CGT pipeline

John Moscariello
21 February 2020
Read
Programming superior cells: translational progress at the Altius Institute for Biomedical Sciences and Umoja Biopharma

Programming superior cells: translational progress at the Altius Institute for Biomedical Sciences and Umoja Biopharma

Shon Green
5 February 2020
Read

Vectors FOCUS

Suspension Culture Methods

Interview

Evolution of culture systems for viral vector production: advantages, challenges and cost considerations

Evolution of culture systems for viral vector production: advantages, challenges and cost considerations

Emmanuelle Cameau, Joseph Capone
6 April 2020
Read
Emerging upstream bioprocessing and analytical tools for vector manufacture

Emerging upstream bioprocessing and analytical tools for vector manufacture

Michael J White
10 March 2020
Read
Establishing a suspension culture-based lentiviral vector bioprocessing facility

Establishing a suspension culture-based lentiviral vector bioprocessing facility

Gabrielle Humphrey
10 March 2020
Read
Suspension systems in continuous viral vector production processes

Suspension systems in continuous viral vector production processes

Felipe Tapia
10 March 2020
Read
Key considerations for the use of suspension culture systems for viral vector manufacturing

Key considerations for the use of suspension culture systems for viral vector manufacturing

Renald Gilbert
26 February 2020
Read

Podcast

Evolution of culture systems for viral vector production: advantages, challenges and cost considerations – Podcast

Evolution of culture systems for viral vector production: advantages, challenges and cost considerations – Podcast

Emmanuelle Cameau, Joseph Capone
10 March 2020
Listen

Expert Insight

Development and scale-up of suspension culture processes for viral vector manufacturing: challenges and considerations

Development and scale-up of suspension culture processes for viral vector manufacturing: challenges and considerations

Helen Young, Philip Probert
10 March 2020
Read

Journal articles

Perspective

Clinical Update: Breaking New Ground

Clinical Update: Breaking New Ground

Sven Kili
6 February 2020
Read

Interview

Tackling the plasmid supply bottleneck

Tackling the plasmid supply bottleneck

Marco Ferrari, Stefano Baila
23 January 2020
Read
Building for future success: the Syncona Partners model

Building for future success: the Syncona Partners model

Martin Murphy
31 January 2020
Read
State of the Industry: The Financial, Clinical, and Scientific Landscape for Cell and Gene Therapies

State of the Industry: The Financial, Clinical, and Scientific Landscape for Cell and Gene Therapies

Janet Lynch Lambert
31 January 2020
Read
Analysing clinical trends for cell & gene therapy in neurodegenerative diseases

Analysing clinical trends for cell & gene therapy in neurodegenerative diseases

Roger Barker
3 February 2020
Read

Commercial Insights

Cell & Gene Therapy Commercial Insight – December 2019

Cell & Gene Therapy Commercial Insight – December 2019

Mark Curtis, Richard Philipson
5 February 2020
Read
Cell & Gene Therapy Commercial Insight – January 2020

Cell & Gene Therapy Commercial Insight – January 2020

Mark Curtis, Richard Philipson
20 February 2020
Read

Webinars